PHAT

SEC source: 0001209191-23-033025 · doc4.xml · derivative · entry 5

Topper James N · CIK 0001341382 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-05-24

F5 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-23-033025 · doc4.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,596

F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-23-033020 · doc4.xml · derivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-05-24

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-23-033020 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-23-033017 · doc4.xml · derivative · entry 2

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-05-24

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-23-033017 · doc4.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-23-031647 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,466

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.

F2 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 12.87 and 13.06. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-023989 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,567

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.20 to $8.50. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-023990 · doc4.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,500

SEC source: 0001209191-23-023751 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,290

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.79 to $7.85. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-023749 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,576

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.

F2 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

SEC source: 0001209191-23-016002 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,371

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022.

F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-016023 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,015

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.

F2 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.3385 to $8.5524. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-009192 · doc4.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.59 to $8.00. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-004341 · doc4.xml · nonDerivative · entry 2

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,807

F3 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-004341 · doc4.xml · derivative · entry 4

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2033-01-18

F4 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-23-004341 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,628

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.

SEC source: 0001209191-23-004337 · doc4.xml · derivative · entry 3

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2033-01-18

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-23-004337 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,047

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,706 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.

SEC source: 0001209191-23-004339 · doc4.xml · derivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-01-18

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-23-004339 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,567

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 2,596 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.

SEC source: 0001209191-23-003151 · doc4.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

SEC source: 0001209191-22-058619 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,720

F1 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.90. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-058627 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,341

F1 · price: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.8716. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-051239 · doc4.xml · derivative · entry 1

Topper James N · CIK 0001341382 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-09-21

F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on September 22, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following two years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-22-048472 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,246

F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.

SEC source: 0001209191-22-048473 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,500

F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-22-048471 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,971

F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,093 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.

SEC source: 0001209191-22-032581 · doc4.xml · derivative · entry 1

FIELDS HEIDI · CIK 0001014330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-22-032588 · doc4.xml · derivative · entry 1

Stenhouse Mark · CIK 0001734751 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-22-032574 · doc4.xml · derivative · entry 1

COLA MICHAEL F · CIK 0001188940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-22-032578 · doc4.xml · derivative · entry 1

KARBE FRANK · CIK 0001276700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0001209191-22-032586 · doc4.xml · derivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-22-032584 · doc4.xml · derivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-22-031080 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,595

F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-22-031085 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-22-031090 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,378

F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-22-029453 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 785,700

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.00 to $8.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-029451 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,595

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.28 to $7.56. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-029446 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.90. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-029442 · doc4.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

SEC source: 0001209191-22-025660 · doc4.xml · derivative · entry 1

KARBE FRANK · CIK 0001276700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-04-24

F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0001209191-22-023561 · doc4.xml · derivative · entry 2

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-04-04

F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on April 5, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-22-023561 · doc4.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · shares: Represents restricted stock units ("RSUs") granted on April 5, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of April 5, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001395064-22-000040 · wf-form4_164747580130121.xml · derivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,359,304 shares

Expires 2029-05-07

F1 · derivative.exercise_price: On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.

F1 · shares: On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.

SEC source: 0001395064-22-000040 · wf-form4_164747580130121.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,459,286

F1 · shares: On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.

SEC source: 0001395064-22-000040 · wf-form4_164747580130121.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,459,304

F1 · shares: On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.

F1 · price: On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.

SEC source: 0001209191-22-004488 · doc4.xml · derivative · entry 3

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,250

Underlying: Common Stock · 206,250 shares

Expires 2032-01-18

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-22-004488 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,095

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,705 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2021, July 2021 and January 2022.

SEC source: 0001209191-22-004492 · doc4.xml · derivative · entry 3

Guzzo Anthony J. · CIK 0001432098 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-01-18

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.